Pre-fibrillar α-synuclein variants with impaired Β-structure increase neurotoxicity in parkinson's disease models

EMBO Journal

Volumn 28, Issue 20, 2009, Pages 3256-3268

  Karpinar, Damla Pinar ^a,b,c   Balija, Madhu Babu Gajula ^a,b,c   Kügler, Sebastian ^b,d   Opazo, Felipe ^b,d   Rezaei Ghaleh, Nasrollah ^a   Wender, Nora ^e   Kim, Hai Young ^a   Taschenberger, Grit ^d   Falkenburger, Björn H ^b,d   Heise, Henrike ^a   Kumar, Ashutosh ^a   Riedel, Dietmar ^a   Fichtner, Lars ^b,d   Voigt, Aaron ^b,d   Braus, Gerhard H ^b,d   Giller, Karin ^a   Becker, Stefan ^a   Herzig, Alf ^a   Baldus, Marc ^a   Jäckle, Herbert ^a   Eimer, Stefan ^b,e   Schulz, Jörg B ^b,d   Griesinger, Christian ^a,b   Zweckstetter, Markus ^a,b   more..

^a MAX PLANCK INSTITUTE FOR BIOPHYSICAL CHEMISTRY   (Germany)

^b Deutsche Forschungsgemeinschaft   (Germany)

^c INTERNATIONAL MAX PLANCK RESEARCH SCHOOL FOR MOLECULAR BIOLOGY   (Germany)

^d UNIVERSITY OF GÖTTINGEN   (Germany)

^e EUROPEAN NEUROSCIENCE INSTITUTE   (Germany)

Author keywords

A synuclein; Neurodegeneration; Oligomer; Parkinson?s disease; Structure

Indexed keywords

ALPHA SYNUCLEIN; OLIGOMER;

ARTICLE; BEHAVIOR DISORDER; BIOPHYSICS; CAENORHABDITIS ELEGANS; CORRELATION ANALYSIS; DROSOPHILA MELANOGASTER; IN VIVO STUDY; MAMMAL; NERVE CELL; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN EXPRESSION; STRUCTURE ANALYSIS; TISSUE CULTURE CELL;

ALPHA-SYNUCLEIN; ANIMALS; ANIMALS, GENETICALLY MODIFIED; BRAIN; CAENORHABDITIS ELEGANS; CELL LINE; DISEASE MODELS, ANIMAL; DROSOPHILA; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; NEURONS; PARKINSON DISEASE; PROTEIN MULTIMERIZATION; PROTEIN STRUCTURE, SECONDARY; RATS;

CAENORHABDITIS ELEGANS; DROSOPHILA MELANOGASTER; MAMMALIA;

EID: 70350338222     PISSN: 02614189     EISSN: 14602075     Source Type: Journal    
DOI: 10.1038/emboj.2009.257     Document Type: Article

References (52)

1. Ader C, Schneider R, Seidel K, Etzkorn M, Becker S, Baldus M (2009) Structural rearrangements of membrane proteins probed by water-edited solid-state NMR spectroscopy. J Am Chem Soc 131: 170-176
2. Bertoncini CW, Jung YS, Fernandez CO, Hoyer W, Griesinger C, Jovin TM, Zweckstetter M (2005) Release of long-range tertiary interactions potentiates aggregation of natively unstructured alpha-synuclein. Proc Natl Acad Sci USA 102: 1430-1435
3. Bischof J, Maeda RK, Hediger M, Karch F, Basler K (2007) An optimized transgenesis system for Drosophila using germ-line-specific phiC31 integrases. Proc Natl Acad Sci USA 104: 3312-3317
4. Brenner S (1974) The genetics of Caenorhabditis elegans. Genetics 77: 71-94
5. Chen L, Feany MB (2005) Alpha-synuclein phosphorylation controls neurotoxicity and inclusion formation in a Drosophila model of Parkinson disease. Nat Neurosci 8: 657-663
6. Cheon M, Chang I, Mohanty S, Luheshi LM, Dobson CM, Vendruscolo M, Favrin G (2007) Structural reorganisation and potential toxicity of oligomeric species formed during the assembly of amyloid fibrils. PLoS Comput Biol 3: 1727-1738
7. Chimon S, Shaibat MA, Jones CR, Calero DC, Aizezi B, Ishii Y (2007) Evidence of fibril-like beta-sheet structures in a neurotoxic amyloid intermediate of Alzheimer0s beta-amyloid. Nat Struct Mol Biol 14: 1157-1164
8. Conway KA, Lee SJ, Rochet JC, Ding TT, Williamson RE, Lansbury Jr PT (2000) Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson?s disease: implications for pathogenesis and therapy. Proc Natl Acad Sci USA 97: 571-576
9. Cookson MR, van der Brug M (2008) Cell systems and the toxic mechanism(s) of alpha-synuclein. Exp Neurol 209: 5-11
10. Cooper AA, Gitler AD, Cashikar A, Haynes CM, Hill KJ, Bhullar B, Liu K, Xu K, Strathearn KE, Liu F, Cao S, Caldwell KA, Caldwell GA, Marsischky G, Kolodner RD, Labaer J, Rochet JC, Bonini NM, Lindquist S (2006) Alpha-synuclein blocks ER-Golgi traffic and Rab1 rescues neuron loss in Parkinson?s models. Science 313: 324-328
11. Eliezer D, Kutluay E, Bussell Jr R, Browne G (2001) Conformational properties of alpha-synuclein in its free and lipid-associated states. J Mol Biol 307: 1061-1073
12. Feany MB, Bender WW (2000) A Drosophila model of Parkinson0s disease. Nature 404: 394-398
13. Fredenburg RA, Rospigliosi C, Meray RK, Kessler JC, Lashuel HA, Eliezer D, Lansbury Jr PT (2007) The impact of the E46K mutation on the properties of alpha-synuclein in its monomeric and oligomeric states. Biochemistry 46: 7107-7118
14. Fung BM, Khitrin AK, Ermolaev K (2000) An improved broadband decoupling sequence for liquid crystals and solids. J Magn Reson 142: 97-101
15. Ganetzky B, Flanagan JR (1978) On the relationship between senescence and age-related changes in two wild-type strains of Drosophila melanogaster. Exp Gerontol 13: 189-196
16. George JM, Jin H, Woods WS, Clayton DF (1995) Characterization of a novel protein regulated during the critical period for song learning in the zebra finch. Neuron 15: 361-372
17. Goedert M (2001) Alpha-synuclein and neurodegenerative diseases. Nat Rev Neurosci 2: 492-501
18. Gorbatyuk OS, Li S, Sullivan LF, Chen W, Kondrikova G, Manfredsson FP, Mandel RJ, Muzyczka N (2008) The phosphor-ylation state of Ser-129 in human alpha-synuclein determines neurodegeneration in a rat model of Parkinson disease. Proc Natl Acad Sci USA 105: 763-768
19. Greenbaum EA, Graves CL, Mishizen-Eberz AJ, Lupoli MA, Lynch DR, Englander SW, Axelsen PH, Giasson BI (2005) The E46K mutation in alpha-synuclein increases amyloid fibril formation. J Biol Chem 280: 7800-7807
20. Hamamichi S, Rivas RN, Knight AL, Cao S, Caldwell KA, Caldwell GA (2008) Hypothesis-based RNAi screening identifies neuropro-tective genes in a Parkinson0s disease model. Proc Natl Acad Sci USA 105: 728-733
21. Heise H, Celej MS, Becker S, Riedel D, Pelah A, Kumar A, Jovin TM, Baldus M (2008) Solid-state NMR reveals structural differences between fibrils of wild-type and disease-related A53T mutant alpha-synuclein. J Mol Biol 380: 444-450
22. Heise H, Hoyer W, Becker S, Andronesi OC, Riedel D, Baldus M (2005) Molecular-level secondary structure, polymorphism, and dynamics of full-length alpha-synuclein fibrils studied by solid-state NMR. Proc Natl Acad Sci USA 102: 15871-15876
23. Hoyer W, Antony T, Cherny D, Heim G, Jovin TM, Subramaniam V (2002) Dependence of alpha-synuclein aggregate morphology on solution conditions. J Mol Biol 322: 383-393
24. Iwai A, Masliah E, Yoshimoto M, Ge N, Flanagan L, de Silva HA, Kittel A, Saitoh T (1995) The precursor protein of non-A beta component of Alzheimer0s disease amyloid is a presynaptic protein of the central nervous system. Neuron 14: 467-475
25. Jensen PH, Nielsen MS, Jakes R, Dotti CG, Goedert M (1998) Binding of alpha-synuclein to brain vesicles is abolished by familial Parkinson0s disease mutation. J Biol Chem 273: 26292-26294
26. Kayed R, Head E, Thompson JL, McIntire TM, Milton SC, Cotman CW, Glabe CG (2003) Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 300: 486-489
27. Kugler S, Hahnewald R, Garrido M, Reiss J (2007) Long-term rescue of a lethal inherited disease by adeno-associated virus-mediated gene transfer in a mouse model of molybdenum-cofactor deficiency. Am J Hum Genet 80: 291-297
28. Kuwahara T, Koyama A, Gengyo-Ando K, Masuda M, Kowa H, Tsunoda M, Mitani S, Iwatsubo T (2006) Familial Parkinson mutant alpha-synuclein causes dopamine neuron dysfunction in transgenic Caenorhabditis elegans. J Biol Chem 281: 334-340
29. Lakso M, Vartiainen S, Moilanen AM, Sirvio J, Thomas JH, Nass R, Blakely RD, Wong G (2003) Dopaminergic neuronal loss and motor deficits in Caenorhabditis elegans overexpressing human alpha-synuclein. J Neurochem 86: 165-172
30. Lashuel HA, Lansbury Jr PT (2006) Are amyloid diseases caused by protein aggregates that mimic bacterial pore-forming toxins? Q Rev Biophys 39: 167-201
31. Lesne S, Koh MT, Kotilinek L, Kayed R, Glabe CG, Yang A, Gallagher M, Ashe KH (2006) A specific amyloid-beta protein assembly in the brain impairs memory. Nature 440: 352-357
32. Masliah E, Rockenstein E, Veinbergs I, Mallory M, Hashimoto M, Takeda A, Sagara Y, Sisk A, Mucke L (2000) Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders. Science 287: 1265-1269
33. Masuda M, Dohmae N, Nonaka T, Oikawa T, Hisanaga S, Goedert M, Hasegawa M (2006) Cysteine misincorporation in bacterially expressed human alpha-synuclein. FEBS Lett 580: 1775-1779
34. Meredith GE, Sonsalla PK, Chesselet MF (2008) Animal models of Parkinson0s disease progression. Acta Neuropathol 115: 385-398
35. Narhi L, Wood SJ, Steavenson S, Jiang Y, Wu GM, Anafi D, Kaufman SA, Martin F, Sitney K, Denis P, Louis JC, Wypych J, Biere AL, Citron M (1999) Both familial Parkinson0s disease mutations accelerate alpha-synuclein aggregation. J Biol Chem 274: 9843-9846
36. Nass R, Blakely RD (2003) The Caenorhabditis elegans dopaminer-gic system: opportunities for insights into dopamine transport and neurodegeneration. Annu Rev Pharmacol Toxicol 43: 521-544
37. Norris EH, Giasson BI, Lee VM (2004) Alpha-synuclein: normal function and role in neurodegenerative diseases. Curr Top Dev Biol 60: 17-54
38. Opazo F, Krenz A, Heermann S, Schulz JB, Falkenburger BH (2008) Accumulation and clearance of alpha-synuclein aggregates demonstrated by time-lapse imaging. J Neurochem 106: 529-540
39. Ostrerova N, Petrucelli L, Farrer M, Mehta N, Choi P, Hardy J, Wolozin B (1999) alpha-Synuclein shares physical and functional homology with 14-3-3 proteins. J Neurosci 19: 5782-5791
40. Outeiro TF, Lindquist S (2003) Yeast cells provide insight into alpha-synuclein biology and pathobiology. Science 302: 1772-1775
41. Periquet M, Fulga T, Myllykangas L, Schlossmacher MG, Feany MB (2007) Aggregated alpha-synuclein mediates dopaminergic neu-rotoxicity in vivo. J Neurosci 27: 3338-3346
42. Petkova AT, Leapman RD, Guo Z, Yau WM, Mattson MP, Tycko R (2005) Self-propagating, molecular-level polymorphism in Alzheimer0s beta-amyloid fibrils. Science 307: 262-265
43. Saudou F, Finkbeiner S, Devys D, Greenberg ME (1998) Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions. Cell 95: 55-66
44. Seidel K, Lange A, Becker S, Hughes CE, Heise H, Baldus M (2004) Protein solid-state NMR resonance assignments from (C-13, C-13) correlation spectroscopy. Phys Chem Chem Phys 6: 5090-5093
45. Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M (1997) Alpha-synuclein in Lewy bodies. Nature 388: 839-840
46. Sunde M, Blake C (1997) The structure of amyloid fibrils by electron microscopy and X-ray diffraction. Adv Protein Chem 50: 123-159 (Pubitemid 27449487)
47. Tabrizi SJ, Orth M, Wilkinson JM, Taanman JW, Warner TT, Cooper JM, Schapira AH (2000) Expression of mutant alpha-synuclein causes increased susceptibility to dopamine toxicity. Hum Mol Genet 9: 2683-2689
48. van Ham TJ, Thijssen KL, Breitling R, Hofstra RM, Plasterk RH, Nollen EA (2008) C. elegans model identifies genetic modifiers of alpha-synuclein inclusion formation during aging. PLoS Genet 4: e1000027
49. Vilar M, Chou HT, Luhrs T, Maji SK, Riek-Loher D, Verel R, Manning G, Stahlberg H, Riek R (2008) The fold of alpha-synuclein fibrils. Proc Natl Acad Sci USA 105: 8637-8642
50. Volles MJ, Lansbury Jr PT (2007) Relationships between the sequence of alpha-synuclein and its membrane affinity, fibrillization propensity, and yeast toxicity. J Mol Biol 366: 1510-1522
51. Zhou DH, Kloepper KD, Winter KA, Rienstra CM (2006) Band-selective 13C homonuclear 3D spectroscopy for solid proteins at high field with rotor-synchronized soft pulses. J Biomol NMR 34: 245-257
52. Zhou W, Hurlbert MS, Schaack J, Prasad KN, Freed CR (2000) Overexpression of human alpha-synuclein causes dopamine neuron death in rat primary culture and immortalized mesencephalon-derived cells. Brain Res 866: 33-43